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A novel tankyrase inhibitor, 
MSC2504877, enhances the effects 
of clinical CDK4/6 inhibitors
Malini Menon1, Richard Elliott1, Leandra Bowers1, Nicolae Balan1, Rumana Rafiq1, 
Sara Costa-Cabral1, Felix Munkonge1, Ines Trinidade1, Roderick Porter2, Andrew D. Campbell3, 
Emma R. Johnson3, Christina Esdar4, Hans-Peter Buchstaller4, Birgitta Leuthner4, 
Felix Rohdich4, Richard Schneider4, Owen Sansom  3, Dirk Wienke4, Alan Ashworth1,5 & 
Christopher J. Lord1
Inhibition of the PARP superfamily tankyrase enzymes suppresses Wnt/β-catenin signalling in tumour 
cells. Here, we describe here a novel, drug-like small molecule inhibitor of tankyrase MSC2504877 that 
inhibits the growth of APC mutant colorectal tumour cells. Parallel siRNA and drug sensitivity screens 
showed that the clinical CDK4/6 inhibitor palbociclib, causes enhanced sensitivity to MSC2504877. 
This tankyrase inhibitor-CDK4/6 inhibitor combinatorial effect is not limited to palbociclib and 
MSC2504877 and is elicited with other CDK4/6 inhibitors and toolbox tankyrase inhibitors. The addition 
of MSC2504877 to palbociclib enhances G1 cell cycle arrest and cellular senescence in tumour cells. 
MSC2504877 exposure suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib 
and enhances the suppression of phospho-Rb, providing a mechanistic explanation for these effects. 
The combination of MSC2504877 and palbociclib was also effective in suppressing the cellular 
hyperproliferative phenotype seen in Apc defective intestinal stem cells in vivo. However, the presence 
of an oncogenic Kras p.G12D mutation in mice reversed the effects of the MSC2504877/palbociclib 
combination, suggesting one molecular route that could lead to drug resistance.
Poly(ADP-ribose) polymerases (PARP) family enzymes use β-NAD+ to catalyze the synthesis of poly(ADP-ribose) 
chains on target proteins as a form of post-translational modification, known as PARylation1. PARP enzymes 
regulate a wide range of cellular functions, including roles for PARP1 and PARP2 in DNA repair and roles for 
PARP5A and PARP5B, also known as Tankyrase 1 and Tankyrase 2 (TNKS1,2, collectively termed tankyrases), in 
telomere maintenance, the control of mitosis and the regulation of Wnt signaling1. Exploiting these roles in the 
development of novel therapeutic approaches to cancer has thus far largely been driven through the discovery 
and clinical development of small molecule PARP1 and PARP2 inhibitors, which have recently been approved 
for the treatment of BRCA1 or BRCA2 mutant ovarian and breast cancers2. In addition, the demonstration that 
experimental “toolbox” tankyrase inhibitors can inhibit oncogenic Wnt signaling in colorectal tumour cells3 has 
driven the discovery of additional, drug-like, tankyrase inhibitors that could be used to target tumours that have 
constitutively active Wnt signaling, such as those with premature truncating mutations in the APC tumour sup-
pressor protein4.
Tankyrases regulate canonical Wnt signaling via PARylation of AXIN, a critical member of a multicomponent 
protein complex including APC, that controls the concentration of β-catenin, a key mediator of Wnt signaling. 
The tankyrase dependent PARylation of AXIN1 causes AXIN ubiquitination via RNF146, and its eventual prote-
osomal degradation. This reduction in AXIN concentration impairs the activity of the β-catenin destruction com-
plex and thus enhances Wnt signaling3. Consistent with this role for tankyrases in Wnt signaling regulation, small 
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molecule inhibitors of tankyrase which impair PARylation activity by competing with β-NAD+ for tankyrase 
binding, reduce AXIN PARylation, stabilise the β-catenin destruction complex and thus inhibit Wnt signaling, 
even in tumour cells with APC mutations that otherwise have constitutive Wnt activity3. As well as controlling 
Wnt signaling, tankyrases have also been implicated in the control of Hippo signaling by modulating YAP5 an 
oncoprotein over-expressed in many cancers, which when activated binds to transcription factors including p736 
and Runx27.
The significant potential of being able to target a relatively common oncogenic process such as Wnt signalling 
has led to considerable efforts to discover small molecule inhibitors that target tankyrase. These include XAV9393, 
IWR-1 and IWR-28, JW749, JW5510, WIKI411, K-75612, the ICR series13, NVP-TNKS65614 and G007-LK15. Each of 
these inhibitors have been shown to impair Wnt signalling in vitro, and in some cases, elicit anti-tumour efficacy 
in xenograft and/or genetically engineered mouse models of cancer15. For example, NVP-TNKS656, a modifi-
cation of XAV939, impairs the growth of Wnt-dependent lesions in the MMTV-Wnt1 mouse cancer model14,16, 
JW74 reduces tumour burden in the ApcMin mouse tumour model9 and JW55 impairs the proliferation of intes-
tinal stem cells with Apc mutations in mice10. Likewise, G007-LK (a JW74 derivative), impairs in situ colorectal 
tumours in mice as well as APC mutant human tumour cell xenografts transplanted into recipient animals15. 
However, in most cases, when used as single agents (i.e. not in combination regimens), even when at relatively 
high-concentrations, tankyrase inhibitors appear to only partially impair tumour growth. Furthermore, the ele-
vated doses of tankyrase inhibitors required to elicit tumour inhibition often result in intestinal toxicity, weight 
loss and death in rodents15,17. This suggests that the use of tankyrase inhibitors in appropriate combination treat-
ment regimens might be more appropriate as these might allow reduced doses of tankyrase inhibitors to elicit 
anti-tumour responses or even enhance the anti-tumour effects of additional agents. For example, in vitro stud-
ies have demonstrated that tankyrase inhibitors can potentiate colorectal tumour cell responses to PI3-Kinase/
AKT pathway inhibitors18 or MAP-kinase pathway (MEK) inhibitors19, suggesting that additional combination 
approaches involving tankyrase inhibitors might be of some value.
Here, we describe the characterisation of a novel small molecule selective tankyrase inhibitor, MSC2504877. 
This selective agent effectively suppresses Wnt signaling, but like previously identified tankyrase inhibitors, has 
limited effectiveness when used as a single agent. In order to understand how MSC2504877 might be used in 
drug combinations, we used parallel in vitro RNA interference and drug sensitivity chemosensitisation screens to 
identify how the tumour cell response to MSC2504877 might be enhanced. This approach identified multiple dif-
ferent components of the canonical Wnt pathway that modulate the response to single agent tankyrase inhibitor 
exposure as well as demonstrating that MSC2504877 can enhance tumour cell responses to inhibitors of the G1 
restriction point kinases CDK4 and CDK6, including the licensed cancer drug palbociclib.
Materials and Methods
Cell lines and cell viability assays. Cell lines were purchased from ATCC, with the exception of MCF10A 
APC mutant isogenic cells (Sigma), and were cultured according to the supplier’s instructions. STR typing of 10 
loci was performed on each cell line using the GenePrint 10 system (Promega) and used to confirm the iden-
tity of cell lines prior to storage. For short term cell survival assays, 500 cells were plated in media containing 
0.5% (v/v) fetal calf serum in each well of 384 well plates. 24 hrs later, media was changed to media containing 
small molecule inhibitors. Cells were then continuously cultured in the presence of small molecule inhibitors 
for a subsequent five days, at which point cell viability was estimated by the use of CellTiter-Glo® Luminescent 
Cell Viability reagent (Promega, used according to the Manufacturer’s instructions). For 14-day drug exposure 
assays, cells were plated in six well plates (500 cells per well). 24 hrs later, media was changed to media containing 
small molecule inhibitors; this media was changed every three days, replenishing small molecule inhibitor each 
time. Cells were continuously cultured for 14 days at which point cells were lysed by adding a covering volume 
of CellTiter-Glo® Luminescent Cell Viability reagent (CTG). CTG was then transferred to white 96 well plates 
for luminescent measurements as per the Manufacturer’s instructions. CTG readings were normalised to values 
derived from cells exposed to the drug vehicle, DMSO, generating Surviving Fractions (SFs). SF were used to 
generate four parameter dose response curves in Prism (Graphpad).
Biochemical assessment of tankyrase activity by ELISA (Autoparylation assay). For analysis 
of TNKS1 and 2 autoparylation and its inhibition by small molecule inhibitors, an ELISA assay was used. These 
were performed in 384 well Glutathione coated microtiter plates (Express capture Glutathione coated plate, 
Biocat, Heidelberg, Germany). Plates were pre-equilibrated with PBS and then incubated with 50 µl of 20 ng/well 
GST-tagged Tnks-1 (1023–1327 aa, prepared in-house) or GST-tagged Tnks-2 (873–1166 aa, prepared in-house) 
which was resuspended in assay buffer (50 mM HEPES, 4 mM Mg-chloride, 0.05% (v/v) Pluronic F-68, 2 mM 
DTT, pH 7.7). This incubation was performed overnight at 4 °C. Plates were then incubated at room temperature 
for 20 minutes with 50 µl blocking buffer: 0.05% (v/v) Tween-20, 0.5% (w/v) BSA in PBS. Plates were then washed 
three times with PBS-Tween-20. The PARylation reaction was performed in the presence/absence of tankyrase 
inhibitors in 50 µl reaction solution: 50 mM HEPES, 4 mM Mg-chloride, 0.05% (v/v) Pluronic F-68, 1.4 mM 
DTT, 0.5% (v/v) DMSO, pH 7.7 + 10 µM bio-NAD (Biolog, Life science Inst., Bremen, Germany) for 1 hour at 
30 °C. The reaction was stopped by washing plates three times with PBS-Tween-20. For PAR detection, plates 
were incubated for 30 minutes at room temperature, with 50 µl per well of 20 ng/µl Streptavidin, HRP conjugate 
(MoBiTec, Göttingen, Germany) resuspended in PBS + 0.05% (v/v) Tween-20 + 0.01% (w/v) BSA. After wash-
ing three times with PBS-Tween-20, 50 µl of SuperSignal ELISA Femto Maximum sensitivity substrate solution 
(ThermoFisherScientific (Pierce), Bonn, Germany) was added to each well. Following a one-minute incubation 
at room temperature, luminescence signals (700 nm) were measured with an Envision multimode reader (Perkin 
Elmer LAS Germany GmbH). The full value used was the inhibitor-free reaction. The pharmacological zero value 
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used was XAV-939 (Tocris) used at a final concentration of 5 μM. The inhibitory values (IC50) were determined 
using either the program Symyx Assay Explorer® or Condosseo® from GeneData.
TNKS, AXIN2 ELISA. Luminex-based bead assays were employed to assess the level of TNKS and AXIN2 
proteins in cell and ex vivo xenograft lysates. For detection of TNKS, a RIPA cell lysis buffer (10 mM Tris HCl, 
150 mM sodium chloride, 1% NP40, 1% Triton X-100, 0,4% Na-Deoxycholat, 2 mM EDTA, 0,3% SDS) was used 
and TNKS protein was isolated from lysates by incubation with a monoclonal anti-TNKS antibody (Thermo 
Scientific, MA1-41011) bound to fluorescent carboxybeads. Detection of TNKS was achieved with a polyclonal 
anti-TNKS antibody (Santa Cruz, sc-8337) and an appropriate PE-fluorescent secondary antibody. An NP40 cell 
lysis buffer (20 mM Tris/HCl pH 8.0, 150 mM NaCl, 1% (v/v) NP40, 10% (v/v) Glycerol) was used for detection of 
AXIN2. A monoclonal AXIN2 antibody (R&D Systems #MAB6078) bound to fluorescent carboxybeads was used 
for isolation of AXIN2 from lysates. A polyclonal anti-AXIN2 antibody (Cell Signaling #2151) and an appropriate 
PE-fluorescent secondary antibody was used for detection. The amount of isolated TNKS and AXIN2 proteins 
were determined with a Luminex200 device (Luminex Corporation) according to the manufacturer’s instruction 
by counting 100 events per sample.
High-throughput siRNA and small molecule inhibitor screening. To optimise experimental con-
ditions for siRNA screening, we assessed the effectiveness of different transfection reagents and selected con-
ditions that met the following criteria: (i) compared to a mock control (no lipid or siRNA), the transfection of 
non-silencing negative control siRNA caused no more than 20% cell inhibition; (ii) compared to non-silencing 
negative control siRNA, the transfection of PLK1–targeting siRNA caused more than 80% cell inhibition; (iii) 
cell confluency reached 70% within the range of 4–7 days. The later criteria allowed assays to be terminated 
whilst cells were in growth phase. Once optimal conditions had been established, COLO320DM cells were trans-
fected with a Dharmacon SMARTpool 384-well plate-arrayed siRNA library designed to target 714 kinases and 
kinase-related genes, 320 Wnt pathway–associated genes, 80 tumor suppressor genes, and 480 genes recurrently 
altered in human cancers, as described in20. Positive control (siPLK1) and multiple negative controls (siCON1 
and siCON2; Dharmacon, catalog numbers D-001210-01-20 and D-001206-14-20, and AllStar; QIAGEN, cat-
alog number 1027281) were included on every plate. Twenty-four hours after transfection, cell culture media 
containing MSC2504877 (final concentration 0.5 μM) or the drug vehicle was added to cells. Cells were then 
cultured for five additional days, at which point cell viability was estimated using CellTiter-Glo assay (Promega). 
Luminescence values were processed using the cellHTS2 R package21. To evaluate the effect of each siRNA pool 
on cell viability, luminescence measurements from cells that were exposed to the drug vehicle DMSO were log2 
transformed, and then centred to the median value for each plate. Plate-centred data was then scaled to the 
median absolute deviation (MAD) and median of the library as a whole to produce robust Z-scores. To estimate 
the effect of each siRNA on MSC2504877 sensitisation, luminescence measurements from cells that were exposed 
to the MSC2504877were log2 transformed, and then centred to the median value for each plate. Plate centered 
data for cells exposed to MSC2504877 was then normalised according to plate centered data for cells exposed to 
DMSO, generating a Drug Sensitisation score for each siRNA. DE values were then scaled to the median absolute 
deviation (MAD) and median of the library as a whole to produce robust Z-scores, as described previously22. All 
screens were performed in triplicate. Screens judged to have poor dynamic range (Z’ factor ≤ 0)23 or poorly cor-
related replicates (r ≤ 0.7) were excluded during an evaluation of screen quality.
For small molecule screens, cells were plated in 384 well-plates as above. Twenty-four hours later, cell cul-
ture media containing the small molecule inhibitor library plus MSC2504877 or the drug vehicle, DMSO, was 
added to cells. Each small molecule inhibitor was present at eight different concentrations (0.5, 1, 5, 10, 50, 100, 
500 and 1000 nM). Cells were then cultured for five additional days, at which point cell viability was estimated 
using CellTiter-Glo assay (Promega). Luminescence values were processed as described above to produce Drug 
Sensitisation Z scores for each small molecule inhibitor concentration included in the drug library.
Drug synergy estimation. MacSynergyII24 was used to estimate synergy volumes, using data from five day 
drug exposure experiments, as described above.
Western blotting. Whole cell protein lysates were generated by lysis with NP250 buffer (20 mM Tris pH 7.6, 
1 mM EDTA, 0.5% NP40, 235 mM NaCl). Following a 20-minute incubation at 4 °C, the lysates were centrifuged 
and the supernatants were collected. Lysates were electrophoresed using Novex precast Bis-Tris gels (Invitrogen) 
and Western blotted on nitrocellulose membranes. Membranes were immunoblotted at 4 °C overnight using an 
anti-Rb1 antibody (NEB #9309) diluted 1:1000 (v/v). After washing, membranes were then immunoblotted for 
1 hour at room temperature with a secondary antibody (Li-COR, 926–32210) diluted 1:10,000 (v/v) in 5% (w/v) 
milk. Protein bands were visualised and quantified using the Odyssey FC imaging system and ImageStudio soft-
ware (Li-COR).
Genetically engineered mice. All in vivo experiments in genetically engineered mice were performed 
in accordance with UK Home Office guidelines (Licence 70/8646), and are subject to ethical review by the 
University of Glasgow. The alleles used in this study were Villin-CreERT2 25, Apcfl 26 and KrasLSL-G12D 27. In the con-
text of Villin-CreERT2; Apcfl/fl experiments, recombination was induced through a single intraperitoneal injection 
of tamoxifen at 80 mgkg−1 on two consecutive days, while in Villin-CreERT2; Apcfl/fl; KrasLSL-G12D/+ experiments, 
recombination was induced with intraperitoneal injection of 80 mgkg−1 tamoxifen on a single occasion. In both 
experimental settings, pharmacological intervention began 24 hours post initial induction, with palbociclib for-
mulated in a solution of sodium lactate (pH 4) in H2O, and MSC2504877 formulated in a solution of 0.5% meth-
ycellulose in H2O, with each respectively administered by oral gavage once or twice daily at the appropriate dose. 
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For analysis of cellular proliferation, 250 ul of 5-bromo-2′-deoxyuridine (BrdU) (Amersham) was administered 
by intraperitoneal injection at 2 hrs prior to sampling.
Immunohistochemistry/RNAscope. Immunohistochemistry or RNA in situ hybridisation was per-
formed throughout this study using formalin fixed paraffin embedded tissue specimens and standard proto-
cols. Primary antibodies used for immunohistochemistry in relation to this study were α-BrdU (BD Biosciences 
#347580, 1:200) and α-p21CIP/WAF (HUGO-291, CNIO, Madrid). RNA in situ hybridisation (RNAscope, Advanced 
Cell Diagnostics Ltd.) was used to detect expression of Lgr5 mRNA in tissue specimens using the RNAscope 2.5 
LS detection reagent according to manufacturers’ instructions.
Xenograft tumour model. For the in vivo PD study, animal procedures were performed in accordance 
with the German Laws for Animal Welfare and reviewed and approved by the Hessian Government Body 
(Regierungspräsidium) in Darmstadt (Licence DA\395). Animals were acclimatised a week prior use and gen-
eral health status was monitored during the experiments. Female immunodeficient CB17 SCID mice (Charles 
River) 5- to 7-week-old received subcutaneously implanted tumour cell suspensions of Colo320 (5 Mio Cells in 
100 µl PBS + 1:1 (v/v) matrigel/animal) in the flank. Tumours were growing until a tumour volume range from 
300–800 mm³ (calculated L × W × W/2 from digital calliper measurements). Mice with appropriate tumour 
volume were stratified into control & treatment groups (n = 5/group). Administrations of vehicle or compound 
(formulated in 0.5% Methocel/0.25% Tween20/water) were orally given by gavage and tumours were collected at 
the respective time points after treatments for subsequent analysis.
Results
MSC2504877 selectively inhibits tankyrase activity and growth of APC deficient cell lines. We 
identified precursors of MSC2504877 (Fig. 1A) from a small molecule screen of roughly half a million com-
pounds, where catalytic inhibition of recombinant TNKS1 was assessed in a cell free assay (Buchstaller et al., 
manuscript in preparation). Hit-to-lead and lead optimisation efforts focused on improving the metabolic stabil-
ity and solubility of the original hit matter and resulted in the identification of MSC2504877 (Buchstaller et al., 
manuscript in preparation).
Using in vitro biochemical assays, we found that MSC2504877 inhibited TNKS1 activity with an IC50 of 
0.0007 μM and PARP1 activity with an IC50 of 0.54 μM, a 771-fold selectivity for TNKS1 (Fig. 1B,C). Inhibition 
of tankyrase PARylation causes a decreased level of AXIN degradation, increased activity of the β-catenin 
destruction complex and a decreased level of β-catenin3. Western blotting of lysates derived from APC mutant 
COLO320DM colorectal tumour cells exposed to MSC2504877 indicated that MSC2504877 increased AXIN2 
protein levels and decreased β-catenin levels (Fig. 1D), suppressed canonical Wnt signalling in SW480 cell line 
that stably expresses luciferase driven by a TCF-dependent promoter (Supplementary Fig. 1) and suppressed 
mRNA levels of two key Wnt-driven transcripts, RUNX2 and AXIN2, as assessed by qRT-PCR (Supplementary 
Fig. 2). MSC2504877 also caused tankyrase levels to rise (Fig. 1D), consistent with MSC2504877 inhibiting 
autoPARylation and subsequent degradation of tankyrase3. These qualitative estimates of MSC2504877 cellu-
lar activity were confirmed by the use of quantitative, antibody-based detection of AXIN2 and TNKS (using a 
luminex-based detection system). This suggested that MSC2504877 increased both AXIN2 (Fig. 1E) and TNKS 
(Fig. 1F) protein levels. We also assessed whether MSC2504877 modulated tumoral Wnt signalling in vivo. 
To do this, we administered MSC2504877 (30 mg/kg) to mice bearing APC mutant COLO320DM tumour cell 
xenografts and recovered tumours for analysis 2–18 hours later. Using the luminex-based system, we found 
that MSC2504877 elicited an increase in both TNKS and AXIN2 levels in tumours, peaking at 6–10 hours after 
drug administration and falling 18 hours after MSC2504877 treatment (Fig. 1G,H), a time course which was 
shifted when compared to the compound concentration time profile in mice (ttmax = 0.5 h, Cmax = 7 µg/mL; 
Cl = 2.72 L/h/kg, Fig. 1I), and thus in agreement with a turnover PK/PD model for a single dose administration 
of MSC2504877. Taken together, these observations suggested that MSC2504877 inhibited TNKS and Wnt sig-
nalling, both in vitro and in vivo.
Previously described tankyrase inhibitors elicit synthetic lethality in tumour cells with APC tumour sup-
pressor gene defects3. In the first instance, we assessed the cell inhibitory properties of MSC2504877 in an 
isogenic pair of APC wild type (APCWT) and APC defective (APC−/−) cells lines derived from the MCF10A 
non-tumour epithelial cell line. In this model, APC gene defects were generated by deletion of 17 bp within exon 
16 of APC using gene targeting. In cell viability assays where APCWT and APC−/− isogenic cells were exposed to 
MSC2504877 for a five-day period, MSC2504877 significantly inhibited the survival of APC−/− cells, compared 
to APCWT cells (Fig. 2A, ANOVA p = 0.005). To assess whether this selectivity could also be achieved in colorec-
tal tumour cell lines with naturally occurring APC gene mutations, we assessed the effect of MSC2504877 in 
APC mutant (p.S811* homozygous) COLO320DM and APC wild type RKO colorectal tumour cell lines. In both 
five-day and two-week drug exposure survival assays, we found that MSC2504877 had a significantly greater 
effect in COLO320DM cells than in RKO cells (Fig. 2B ANOVA p = 0.012 (five-day assay) and Fig. 2C ANOVA 
p = 0.001 (14-day assay)). We also noted that the cell inhibitory effect of MSC2504877 on COLO320DM was sig-
nificantly more profound when an extended drug exposure of 14 days was used, compared to a five-day exposure 
(Fig. 2B,C).
Given the interest in using tankyrase inhibitors to target APC mutant colorectal cancers (CRC), we also 
assessed MSC2504877 sensitivity in a panel of CRC tumour cell lines. We carried out MSC2504877 sensitivity 
assays in 24 APC mutant models as well as five APC wild type models and found that the responses in the APC 
mutant models were varied, with some APC mutant models, such as COLO201, HCT15, HGC27 and LOVO, 
being profoundly resistant to single agent tankyrase inhibitor exposure (Fig. 2D). Although the use of isogenic 
cell lines clearly identified APC synthetic lethality with MSC2504877 (Fig. 2A), the varied responses in the panel 
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Figure 1. MSC2504877 is a novel, drug-like, small molecule tankyrase inhibitor. (A) Structure of MSC2504877. 
(B) Dose-response curve illustrating the inhibition of recombinant tankyrase (TNKS) or PARP1 with 
MSC2504877A. Tankyrase activity was assayed using the PARP domain of recombinant human Tankyrase 
(TNKS) or PARP1 in an ELISA assay. Mean dose response data from three independent experiments is shown. 
Error bars represent standard error of the mean (SEM). (C) Table illustrating IC50 concentrations obtained 
for MSC2504877A and two toolbox tankyrase inhibitors. TNKS, TNKS2 and PARP1 activity was determined 
as in (B). (D) Western blot illustrating tankyrase stabilisation, suppression of β-catenin and stabilisation of 
Axin 2 protein levels in COLO320DM (APC mutant) colorectal tumour cells exposed to MSC2504877 for 
24 hours as shown. α-Tubulin was used as loading control (E,F). Luminex antibody-based detection of AXIN2 
and TNKS in COLO320DM cells exposed MSC2504877 in vitro. Dose response data from three independent 
experiments are shown; error bars represent standard deviations (G,H) Luminex detection of AXIN2 and 
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of CRC tumour cell lines suggested that APC mutation alone might not be a fully penetrant biomarker of sin-
gle agent tankyrase inhibitor response; we also did not find that the position of truncating mutations in APC 
correlated with MSC2504877, as has been suggested for other tankyrase inhibitors4. We assessed whether other 
cancer driver gene alterations found in CRC, such as those in TP53, SMAD4, PIK3CA, KRAS, ARID1A, SOX9 and 
FAM123B correlated with sensitivity to MSC2504877, but did not find, in this tumour cell line panel at least, that 
gene mutations/copy number alterations in any of these strongly correlated with tankyrase inhibitor response.
Integrated RNA interference and small molecule chemosensitisation screens identify 
CDK4/6 inhibition as a determinant of MSC2504877 sensitivity. To better understand what could 
drive sensitivity to MSC2504877, we carried out parallel RNA interference (RNAi) and small molecule/drug 
high-throughput chemosensitisation screens using MSC2504877 in APC mutant colorectal cancer tumour cell 
lines.
For the small molecule/drug chemosensitisation screens, we plated COLO320DM cells (APC p.S811* 
homozygous and KRAS wild type) or SW480 cells (APC mutation p.N125K;p.F1197fs;p.S1278* heterozygous, 
KRAS mutation p.G12C heterozygous) in 384 well plates containing MSC2504877 or the drug vehicle (DMSO), 
combined with a library of 80 small molecule inhibitors that are either already used in the treatment of cancer, or 
are in late stage development. To maximize the likelihood of identifying chemosensitization effects, each small 
molecule inhibitor in the library was present at eight different concentrations. Cells were then exposed to drugs 
for five continuous days, at which point cell viability was estimated by the use of Cell TitreGLo reagent (Fig. 3A). 
Each tumour cell line was screened in triplicate, with median effects being used to estimate MSC2504877 
sensitivity-causing effects. Replica screens showed a high level of reproducibility between independent replicas 
(r2 > 0.7) and a suitable dynamic range (Z’ > 0.5).
To identify candidate chemosensitization effects, we calculated Drug Sensitisation (DE) robust Z scores 
describing the effect of each library drug on the response to MSC2504877; we defined those library drugs that 
elicited DE Z < −2 effects (approximately equivalent to p < 0.05) with at least two different concentrations as 
being candidate sensitivity causing effects (Fig. 3B,C). Amongst these sensitization effects, we noted the pres-
ence of previously reported effects, including tankyrase inhibitor sensitization caused by an EGFR inhibitor28, 
canertinib (MSC2504877 sensitisation effect in COLO320DM) and MSC2504877 sensitization caused by the 
multikinase inhibitor dasatinib19 (MSC2504877 sensitisation effect in both SW480 and COLO320DM) giving 
us some confidence in the results. Our intermediate aim was to identify sensitization effects that operated in a 
variety of APC mutant colorectal tumour cell lines; by intersecting the data from both COLO320DM and SW480 
screens, we identified two drugs that caused MSC2504877 sensitivity in both: the mutlikinase inhibitor, dasatinib, 
identified in earlier work19, and the CDK4/6 kinase inhibitor palbociclib (PF-332991).
Alongside these drug combination screens, we also carried out short interfering (si)RNA chemosensitisation 
screens using MSC2504877 (Fig. 4A). COLO320DM cells were reverse transfected in 384 well plates using an 
siRNA library designed to target 1143 genes, including a panel of protein kinases, genes included in the cancer 
gene census29 and also, genes implicated in Wnt signaling, given the role of tankyrases in this molecular pathway. 
Twenty-four hours after siRNA transfection, cells were either exposed to MSC2504877 or the drug vehicle for a 
subsequent five days, at which point cell viability was estimated by the use of Cell TitreGlo reagent (Fig. 4A). We 
performed three replica screens, and combined the replicas in the final analysis. Replica screens showed a high 
level of reproducibility between independent replicas (r2 > 0.7) and a suitable dynamic range (Z’ > 0.5).
To identify candidate sensitivity and resistance-causing effects, we calculated Drug Sensitisation Z scores 
describing the effect of siRNA on the response to MSC2504877; we defined those siRNAs that elicited Z < −2 
effects (approximately equivalent to p < 0.05) as being candidate sensitivity-causing effects and, conversely 
defined Z > 2 effects as resistance-causing. Candidate resistance-causing or sensitivity-causing siRNAs are 
illustrated in Fig. 4C. We noted that one of the most profound resistance-causing effects was caused by siRNA 
designed to target AXIN2 (Fig. 4C), an effect that confirmed previous observations made using a first-generation 
small molecule tankyrase inhibitor, XAV939, in APC mutant DLD1 CRC cells3. Using the Z score thresholds 
of Z < −2 (sensitivity) and Z > 2 (resistance), we selected siRNAs for further analysis in validation experi-
ments. Of the 44 siRNAs selected for validation, we found in subsequent experiments that 13 caused sensitiv-
ity to MSC2504877 (FANCA, CDK4, FEN1, CDK7, RANBP17, ERCC3, PDGFA, PDGFRB, ADBRK1, SLC45A3, 
SETD2, CDK6 and PIK3CA) whilst 13 siRNAs caused MSC2504877 resistance (BTRC, RNF43, PMS2, TSC1, 
TSC2, CTNNBIP1, FAT1, BCOR, KREMEN1, PTEN, BCL7A, DCLRE1C, CUL1 and AXIN2) (Fig. 4D). In addi-
tion to AXIN2, we found that a number of other siRNA designed to target modifiers of Wnt signaling caused 
MSC2504877 resistance. These included siRNAs designed to target FAT1 or CTNNBIP1, proteins which normally 
bind β-Catenin and impair its nuclear localization30, and CUL1, BTRC (β-TrCP) and AMER1 (also known as 
FAM123B or WTX), proteins which normally mediate the proteosomal degradation of β-Catenin. These obser-
vations suggested that modulation of a series of additional Wnt pathway components, and specifically those that 
control the level of nuclear β-Catenin, could drive resistance to tankyrase inhibitors, similar to the observations 
made by de la Roche et al., who demonstrated that LEF1 and B9L, proteins that prevent Axin driven degradation 
of β-Catenin, reverse tankyrase inhibitor sensitivity31. We also noted that siRNA targeting PTEN, TSC1 or TSC2 
also caused MSC2504877 resistance (Fig. 4D), implicating the PI3-kinase/mTOR signaling cascade in controlling 
the response to MSC2504877. In terms of sensitivity causing effects, siRNA targeting PIK3CA, the gene encoding 
the catalytic domain of the major PI3-kinase enzyme, was also confirmed (Fig. 4D).
TNKS in COLO320DM xenografts. CB17 SCID mice received 30 mg/kg MSC2504877 via an oral route. At the 
time points indicated, mice were sacrificed and xenografts recovered. Each data point indicates data from one 
animal. (I) Plasma concentration time profile of MSC2504877 after one single oral dose of 30 mg/kg.
www.nature.com/scientificreports/
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Figure 2. MSC2504877 elicits APC synthetic lethality. (A–C) MSC2504877 selectively targets APC defective 
cells. Dose response survival curves are shown for (A) MCF10A APC +/+ and APC −/− isogenic cells, or (B) 
COLO320DM (APC defective) and RKO (APC wild type) colorectal tumour cells continuously exposed 
to MSC2504877 for a total of five days and (C) COLO320DM and RKO cells continuously exposed to 
MSC2504877 for a total of 14 days. Experiments were conducted in in media containing 0.5% (v/v) FCS. 
Dose response data from three independent experiments are shown; error bars represent SEM. p values were 
calculated using ANOVA. (D) MSC2504877 sensitivity in 23 colorectal tumour cell lines. Tumour cell lines were 
profiled for sensitivity to five-day exposure to MSC2504877, as in (B) in media containing 0.5% (v/v) FCS. Bar 
chart illustrating EC50 values is shown.
www.nature.com/scientificreports/
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Figure 3. Small molecule chemosensitisation screens identify palbociclib as a candidate MSC2504877 
sensitising agent. (A) Schematic of MSC2504877 chemosensitisation screens in colorectal tumour cells. 
COLO320DM and SW480 cells were exposed to 80 library drugs (at eight different concentrations, arrayed in 
two 384-well plates) for five continuous days, in the presence or absence of MSC2504877, at which point cell 
viability was estimated. Cell viability data was used to calculate drug sensitisation Z scores. Library drugs that 
elicited Z scores of <−2 at more than one different concentration were selected as candidate MSC2504877 
chemosensitisation effects, and shown in (B,C). (B,C) Bar charts illustrating candidate MSC2504877 
chemosensitisation effects in SW480 cells (B) and COLO320DM cells (C). Dasatinib and palbociclib 
chemosensitisation effects in both cell lines are highlighted.
www.nature.com/scientificreports/
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Figure 4. A RNA interference (RNAi) sensitisation screen identifies candidate MSC2504877 sensitivity- and 
resistance-causing effects. (A) Schematic of RNAi screen in colorectal tumour cells. COLO320DM cells were 
transfected with 1599 different siRNA SMARTPools (arrayed in five different 384 well-plates) and then cultured 
for five continuous days in the presence or absence of MSC2504877. At this point, cell viability was estimated. 
Cell viability data was used to calculate drug sensitisation Z scores. siRNAs that elicited Z scores of <−2 or >2 
were selected as candidate MSC2504877 sensitisation/resistance-causing effects, shown in (C). (B) Scatter plot 
illustrating the effect of control siRNAs on cell viability in COLO320DM cells. siRNA designed to target Polo-
like kinase 1 (PLK1) caused profound cell inhibition, when compared to three different non-targeting siRNAs 
(Allstar, siCON1 and siCON2). (C). Bar chart illustrating drug sensitisation Z scores of “hits” identified in the 
screen. (D) Bar chart illustrating MSC2504877 responses in post-screen validation experiments. COLO320DM 
cells were transfected with SMARTpool siRNA and then exposed to MSC2504877 for five days at which point 
cell viability was estimated. Effects of CDK4 and CDK6 siRNA SMARTpools are highlighted in red, both of 
www.nature.com/scientificreports/
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By cross referencing the results from the small molecule chemosensitisation screens and the siRNA screen, we 
noted that siRNAs targeting CDK4 or CDK6 also caused sensitivity to MSC2504877 (Fig. 4C,D), corroborating 
the results seen with the CDK4/6 inhibitor palbociclib in the small molecule sensitisation screens (Fig. 3). We 
investigated this further, initially by assessing whether sensitivity to MSC2504877 caused by palbociclib was spe-
cific to the COLO320DM model or was also found in additional CRC tumour cell line models.
Tankyrase inhibitor sensitisation by CDK4/6 inhibition is not specific to palbociclib or 
MSC2504877. We confirmed that palbociclib caused MSC2504877 sensitivity in COLO320DM cells 
(Fig. 5A–D) and found that a chemically distinct CDK4/6 inhibitor, abemaciclib (LY2835219, Eli Lily), also elic-
ited a synergstic effect with MSC2504877 (Fig. 5E). Furthermore, we found that a toolbox tankyrase inhibi-
tor, NVP-656, also had a synergistic interaction with palbociclib (Fig. 5F). These observations suggested that 
the CDK4/6 inhibitor vs. tankyrase inhibitor synergistic effects were not specific to MSC2504877 or palboci-
clib. In addition, we assessed whether the MSC2504877 sensitisation effect caused by palbociclib was specific 
to COLO320DM cells. We found that palbociclib/ MSC2504877 synergy existed in SW480 (APC p.Q1338* 
homozygous, KRAS p.G12V homozygous and amplified), SW620 (APC Q1338* homozygous, KRAS p.G12V 
homozygous and amplified) and SW403 (APC mutation p.N125K;p.F1197fs;p.S1278* heterozygous, KRAS muta-
tion p.G12C heterozygous) CRC tumour cell lines (Fig. 5G).
Simultaneous exposure to MSC2504877 and palbociclib enhances G1/S cell cycle arrest and a 
senescence phenotype. CDK4 and CDK6 are cyclin dependent kinases that with their Cyclin D-family 
partners, work within a network of tumour suppressor proteins and oncogenes that control the progression of the 
cell cycle. For example, the tumour suppressor protein, CDKN2A (p16INK4a) inhibits CDK4 and CDK6, events 
that reduce their ability to phosphorylate and inactivate the Rb (RB1) tumour suppressor protein. This function 
of CDKN2A in the CDKN2A, CDK4/6, Rb signaling cascade alters the activity of a series of Rb-controlled E2F 
family transcription factors, which in turn suppress G1/S cell cycle progression. This suppression of G1/S cell 
cycle progression also often leads to cellular senescence. In the absence of CDKN2A, a common driver event in 
human cancers, the control of the G1/S cell cycle checkpoint is impaired. Small molecule CDK4/6 inhibitors, such 
as palbociclib, elicit their anti-tumour effects in part by reinstating the G1/S checkpoint in tumour cells that still 
have the ability to express Rb; this often leads to cellular senescence32. Palbociclib has been approved for use as 
part of drug combination regimens in estrogen receptor positive advanced breast cancer33,34. In colorectal cancers, 
the CDKN2A, CDK4/6, Rb signaling cascade might also control tumourigenesis driven by loss of wild type APC 
function. For example, in a mouse model of adenoma formation, Apc dysfunction causes an increase in Cyclin 
D2 and CDK4 expression and a corresponding increase in hyperphosphorylated Rb35. Furthermore, Cyclin D2 
causes a reduction in enterocyte proliferation and crypt size in Apc-deficient intestinal epithelia, and CDK4/6 
inhibition limits the proliferation of adenomatous cells, but not normal cells, in Apc(Min/+) mice35.
Based on these observations, we assessed whether the combination of palbociclib and MSC2504877 caused 
a change in cell cycle progression. FACS profiling of COLO320DM cells demonstrated that MSC2504877 expo-
sure alone had negligible effects on the cell cycle, whilst, palbociclib caused a modest, concentration dependent, 
increase in the G1 fraction of cells (G1 fraction increased from 56% to 66% in response to 0.3  μM palbociclib 
after 24 hours of treatment and 54% to 60% after 144 hours of treatment) (Fig. 6A). However, in contrast to the 
single agent effects, the combination of MSC2504877 and palbociclib caused a supra-additive increase in the G1 
fraction (G1 fraction increased from 56% to 77% at 24 hours and 54% to 70% at 144 hours, Fig. 6A). We also noted 
that whilst single agent use of either palbociclib or MSC2504877 alone had negligible effects on the proportion 
of COLO320DM cells exhibiting a senescent phenotype (as estimated by β-galactosidase staining), exposure to 
both agents caused a clear increase in β-galactosidase positive cells (Fig. 6B). Taken together, this suggested that 
the synergistic effect of palbociclib when used with MSC2504877, could be explained by a supra-additive effect on 
the G1/S cell cycle checkpoint and the induction of cellular senescence, phenotypes reminiscent of a re-instated 
Rb-mediated signaling cascade.
To investigate the molecular features of this effect, we assessed the expression and phosphorylation status 
of a series of proteins involved in the CDKN2A, CDK4/6, Rb signaling cascade when cells were exposed to a 
palbociclib/MSC2504877 combination (Fig. 6C–E). We found that whilst exposure to palbociclib caused an 
increase in Cyclin D2 and Cyclin E2 levels, presumably a mechanism by which the cells override the G1 cell cycle 
blockade initiated by CDK4/6 inhibition, the addition of MSC2504877 suppressed these Cyclin D2/E2 responses 
(Fig. 6C,D). We also noted a time dependent effect on the levels of phosphorylated Rb (S807–811); as expected, 
palbociclib exposure elicited a decrease in level of phosphorylation after 24 hrs of exposure (Fig. 6E,F). However, 
after 72 hrs, levels of phosphorylated Rb in cells exposed to palbociclib were restored to those in cells exposed to 
the drug vehicle, DMSO (Fig. 6E,F). In contrast, the addition of MSC2504877 to palbociclib maintained the sup-
pression of phosphorylated Rb levels over the 72 hour time course (Fig. 6E,F). These observations, taken together 
with the FACS profiling data, were consistent with the hypothesis that MSC2504877, when combined with palbo-
ciclib, reinforces G1 cell cycle arrest and ultimately causes cells to senesce. The CyclinD2-coding gene, CCND2, is 
a transcriptional target of canonical Wnt signalling. Using RT-PCR, we found that palbociclib exposure caused an 
which significantly enhanced MSC2504877 sensitivity, compared to control, non-targeting siRNAs (Allstar and 
siCON1). Dark grey columns indicate additional MSC2504877 sensitivity-causing siRNAs, whilst light grey 
bars indicate MSC2504877 resistance-causing effects. Validation was carried out in a 384 well-plate five day 
assay. Ratio of survival fraction in the MSC2504877A exposed cells compared to DMSO exposed cells is plotted. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, Student’s t test. Error bars represent SEM from triplicate 
experiments.
www.nature.com/scientificreports/
1 1SCieNTiFiC REPORtS |           (2019) 9:201  | DOI:10.1038/s41598-018-36447-4
Figure 5. CDK4/6 inhibitors sensitise tumour cells to tankyrase inhibitors.(A–C). Dose response cell 
survival curve for COLO32DM cells exposed to (A) MSC2504877 (B) palbociclib, or (C) the combination of 
MSC2504877 plus palbociclib, for five days. Mean effect from three independent experiments is shown; error 
bars represent SEM. (D) Synergy volume plot indicating supra-additive effect of MSC2504877 plus palbociclib 
in COLO320DM cells. Synergy volumes >50 are regarded as strong synergistic effects (E,F). Dose response 
cell survival curve for COLO32DM cells exposed to (E) MSC2504877 plus abemaciclib, or (B) NVP656 plus 
palbociclib, for five days. Mean effect from three independent experiments is shown; error bars represent SEM. 
(G) Bar chart of synergy volumes from MSC2504877 plus palbociclib dose response experiments in colorectal 
tumour cells. Colorectal tumour cells were exposed to MSC2504877 plus palbociclib in triplicate experiments as 
in (A–D). Synergy volumes were calculated using MacSynergyII.
www.nature.com/scientificreports/
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Figure 6. MSC2504877 + palbociclib combination elicits G1 cell cycle effects. (A) Bar chart illustrating cell cycle 
fractions in COLO320DM cells exposed to MSC2504877 plus palbociclib. Numbers in boxes reflect % of total cell 
number. (B) Microscopy images illustrating β-galactosidase staining in COLO320DM cells exposed to MSC2504877 
plus palbociclib. Blue staining indicates β-galactosidase positive cells. Scale bar represents 10 microns. (C) Western 
blot image illustrating Cyclin D2, Cyclin E2 and CDK4 protein levels in COLO320DM cells exposed to MSC2504877. 
Palbociclib causes an increase in Cyclin D2 and Cyclin E2 protein levels, which is suppressed by MSC2504877. (D) 
Bar chart illustrating band densiometry measurements from (C). (E) Western blot image illustrating phospho-Rb 
suppression in COLO320DM cells exposed to MSC2504877 and palbociclib. Palbociclib alone causes a transient 
suppression in phospho-Rb levels (at 24 and 48 hours). The addition of MSC2504877 temporally extends phospho-Rb 
suppression. (F) Bar chart illustrating band densiometry measurements from (E). (G) Bar chart illustrating 
normalised RT-PCR measurements from COLO320DM cells exposed to MSC2504877 plus palbociclib for 24 hours. 
Data shown is from triplicate experiments. Error bars represent SEM.
www.nature.com/scientificreports/
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Figure 7. Palbociclib plus MSC2504877 combination suppresses the intestinal hyperproliferation phenotype 
in Villin-CreERT2; Apcfl/fl mice. (A) Schematic of Villin-CreERT2; Apcfl/fl model system. (B) Images of hematoxylin 
and eosin stained intestinal tissue from Villin-CreERT2; Apcfl/fl mice. Animals received vehicle, MSC2504877, 
palbociclib or a combination of MSC2504877 plus palbociclib for 3 continuous days. Combination HD = high 
dose combination, 50 mg/kg MSC2504877 + 150 mg/kg palbociclib. Combination LD = low dose combination, 
20 mg/kg MSC2504877 + 37.5 mg/kg palbociclib. (C) Images of intestinal tissue from Villin-CreERT2; Apcfl/
fl mice immunohistochemically stained for BrdU incorporation. Mice were treated as in (B). (D) Images of 
intestinal tissue from Villin-CreERT2; Apcfl/fl mice immunohistochemically stained with an RNAscope probe 
directed against Lgr5 mRNA. Mice were treated as in (B). (E) Images of intestinal tissue whole mounts from 
Villin-CreERT2; Apcfl/fl mice stained with an RNAscope probe directed against Lgr5 mRNA. Mice were treated 
as in (B). Arrows in control sample image indicates presence of Lgr5 expression; arrows in combination 
(TNKSi + Palbociclib) treated mice image shows absence of Lgr5 expression. (F) Images of intestinal tissue 
from Villin-CreERT2; Apcfl/fl mice immunohistochemically stained for the presence of p21. Mice were treated as in 
www.nature.com/scientificreports/
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upregulation of CCND2 mRNA levels (Fig. 6G), commensurate with the increase in Cyclin D2 protein levels seen 
earlier (Fig. 6C,D); this increase in CCND2 mRNA levels was reduced to basal levels when cells were also exposed 
to MSC2504877 (Fig. 6G), providing a mechanistic explanation for the combined tumour cell inhibitory effects 
of palbociclib and MSC2504877.
Palbociclib plus MSC2504877 combination suppresses hyperproliferation in Apc defective cells 
in vivo. To assess whether these effects operated in an in vivo setting, we assessed the impact of a 
MSC2504877 + palbociclib combination in genetically engineered mice carrying Villin-CreERT2 and homozygous 
for the Apcfl allele; tamoxifen-induced, Cre-mediated recombination in this mouse model drives homozygous 
deletion of Apc in the entire intestinal epithelium, aberrant activation of the Wnt pathway and as consequence, 
dramatic intestinal crypt expansion36 (Fig. 7A). In the first instance, we dosed Villin-CreERT2; Apcfl/fl mice with 
either single agent MSC2504877 (50 mg/kg), single agent palbociclib (150 mg/kg), or a MSC2504877 (50 mg/kg) 
+ palbociclib (150 mg/kg) combination. Whilst neither single agent drug administration suppressed intestinal 
crypt expansion caused by Apc deletion, the combination of MSC2504877 with palbociclib had a dramatic sup-
pressive effect, as seen both by the gross histology of tissue sections isolated from mice (Fig. 7B), and also a pro-
found reduction in bromodeoxyuridine (BrdU) incorporation in intestinal crypts (Fig. 7C). These effects were 
apparent using a 50 mg/kg MSC2504877 + 150 mg/kg palbociclib combination (“high dose combination”, (HD)), 
as well at lower concentrations of MSC2504877 + palbociclib (20 mg/kg + 37.5 mg/kg, respectively, “low dose 
combination” (LD) Fig. 7B,C). Combined exposure to MSC2504877 + palbociclib also suppressed the expression 
of the archetypal Wnt target gene and stem cell marker Lgr5 (Fig. 7D,E) and combination drug treatment caused 
a profound increase in nuclear p21 (Fig. 7F), consistent with an effect on mechanisms of G1/S cell cycle control.
In many human tumours, including colorectal cancers, loss of function APC mutations co-occur with muta-
tion in KRAS. We also exploited genetically engineered mice to assess whether the presence of a Kras mutation 
might modulate the effects of a tankyrase inhibitor/CDK4/6 inhibitor combination. To do this, we assessed the 
crypt hyper-proliferative phenotype in Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ mice37 (Fig. 7G). By examination of 
the gross histology of tissue sections (Fig. 7H), and BrdU incorporation (Fig. 7I), we found that the presence of 
the KRasG12D mutation reversed the inhibitory effects of the MSC2504877 + palbociclib combination.
Discussion
Here we describe the characterisation of a novel tankyrase inhibitor, MSC2504877. Along with biochemical and 
cellular assays carried out to assess its potency and selectivity, we demonstrate that combination with CDK4/6 
inhibitors has a supra-additive effect on tumour cells. Dissection of this effect suggests that this combinatorial 
effect might be mediated by the ability of MSC2504877 to suppress the upregulation of Cyclin D2 levels. This 
appears to be a distinct mechanism to those proposed for other tankyrase inhibitor combinations. For example, 
the supra-additive effect of a tankyrase inhibitor combined with a MEK inhibitor is proposed to be mediated via 
the ability of tankyrase inhibition to suppress a FGFR2-mediated feedback loop that is otherwise activated by 
MEK inhibition19. Tankyrase inhibitors have been also shown to sensitise lung cancer cells to EGFR inhibition 
through a mechanism that involves stabilisation of angiomotins and inhibition of YAP signalling5. It thus seems 
reasonable to propose that there might be multiple, distinct, routes by which tankyrase inhibition alter the home-
ostatic response to other drugs.
One challenge associated with the development of tankyrase inhibitors as a treatment for cancer has been the 
intestinal toxicity observed in pre-clinical animal models. Wnt/β catenin signalling maintains homeostasis in 
the intestinal epithelium; inhibition of Wnt/β catenin signalling results in terminal differentiation of stem cells 
and loss of crypt structure38,39. It seems possible that the suppression of Wnt/β catenin signalling via tankyrase 
inhibition in intestinal stem cells is an explanation, at least in part, for the intestinal toxicity seen with tankyrase 
inhibitors. This in turn, might challenge the concept of therapeutically targeting canonical Wnt signalling as a 
therapeutic approach. However, preliminary data from a phase 1 clinical trial of WNT974, an inhibitor of por-
cupine (a membrane-bound O-acyltransferase enzyme required for Wnt ligand secretion), reports a manageable 
safety profile as well as suppression of a key Wnt/β catenin target gene, AXIN240. Whether CDK4,6 inhibitors 
might also have combinatorial effects with Porcupine inhibitors or other drug targets in Wnt/β catenin signalling 
cascade remains to be seen.
In summary, MSC2504877 is a novel, drug-like, tankyrase inhibitor that inhibits APC mutant colorectal 
tumour cells. Parallel siRNA and drug sensitivity screens show that the clinical CDK4/6 inhibitor palbociclib, 
causes enhanced sensitivity to MSC2504877. This tankyrase inhibitor - CDK4/6 inhibitor combinatorial effect 
is not limited to palbociclib and MSC2504877 and is elicited with other CDK4/6 inhibitors and other tankyrase 
inhibitors, namely NVP-656. Nevertheless, it is possible that these effects are private to the tankyrase inhibitors/
CDK4/6 inhibitors tested. The addition of MSC2504877 to palbociclib enhances G1 cell cycle arrest and cellular 
senescence. MSC2504877 exposure suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib 
and enhances the suppression of phopho-Rb. Combinatorial effects of MSC2504877 and palbociclib are also seen 
in suppressing the cellular hyperproliferative phenotype seen in Apc defective intestinal stem cells in vivo.
(B). (G) Schematic of Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ model system. (H) Images of hematoxylin and eosin 
stained intestinal tissue from Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ mice. Animals received vehicle, MSC2504877, 
palbociclib or a combination of MSC2504877 plus palbociclib. Combination HD = high dose combination, 
50 mg/kg MSC2504877 + 150 mg/kg palbociclib. Combination LD = low dose combination, 20 mg/kg 
MSC2504877 + 37.5 mg/kg palbociclib. (I) Images of intestinal tissue from Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ 
mice immunohistochemically stained for BrdU incorporation. Mice were treated as in (H).
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